• Mink Therapeutics’ agenT-797 iNKT platform was selected for an ARPA-H-funded effort to enable room-temperature storage of cell therapies.
• The work falls under ARPA-H’s four-year BioStabilization Systems program, with up to USD 87 million committed across the initiative.
• Mink joins the Reversible Ambient Biostabilization team led by Draper, with Likarda and Fresenius Kabi among participants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300757PRIMZONEFULLFEED9836874) on September 30, 2026, and is solely responsible for the information contained therein.